Salix hits new high on Phase III IBS results
This article was originally published in Scrip
Executive Summary
The past seven months have been good ones for Salix Pharmaceuticals, whose stock price has doubled since November, culminating in positive top-line Phase III results for Xifaxan (rifaximin) in the retreatment of irritable bowel syndrome with diarrhea (IBS-D) on 1 July.